| 董敏 孔德胜 赵红丽 梁冬 于春芳 洪珞珈.DC 与CIK细胞治疗难治复发急性髓细胞白血病的近期临床观察[J].,2014,14(1):159-162 |
| DC 与CIK细胞治疗难治复发急性髓细胞白血病的近期临床观察 |
| Recent Clinical Observation on the DC and CIK Cell in the Treatmentof Refractory and Recurrent Acute Myeloid Leukemia |
| |
| DOI： |
| 中文关键词: 突状细胞 细胞因子诱导的杀伤细胞 细胞免疫治疗 急性髓细胞白血病 |
| 英文关键词: Dendritic cells Cytokines induced killer cells Cell immunotherapy Acute Myeoloid Leukemia |
| 基金项目:黑龙江省科技厅课题(QC2012C050) |
|
| 摘要点击次数: 611 |
| 全文下载次数: 912 |
| 中文摘要: |
| 目的：评估自体DC与CIK 细胞治疗难治复发急性髓细胞白血病的近期疗效与安全性。方法：给予20 例难治复发急性髓细
胞白血病患者树突状细胞(DC)与细胞因子诱导的杀伤细胞(CIK)治疗，20 例难治复发的应用同样化疗方案的急性髓细胞白血病
患者做为对照组；治疗后4 周观察两组患者临床疗效和生存质量(KPS)评分，DC 与CIK 细胞治疗前和治疗后1 周检测T细胞亚
群(CD3+、CD3+CD4+、CD3+CD8+、CD3+CD56+)和细胞因子(IL-12、IL-2、IL-7、IFN-酌及TNF-琢)水平的变化。结果：①DC 与CIK 细胞
治疗组有效率和KPS评分明显高于对照组(P<0.05)，所有患者的不良反应轻微，均可耐受。②DC 与CIK 细胞治疗后1 周，患者T
细胞亚群百分比和细胞因子含量较治疗前均明显升高，其中CD3+、CD3+CD56+及IL-12、IL-7 明显升高(P<0.05)。结论：DC与CIK
细胞免疫治疗难治复发急性髓细胞白血病安全有效。 |
| 英文摘要: |
| Objective: To evaluate the efficacy and safety of autologous DC and CIK cell in the treatment of refractory and
recurrent acute myeloid leukemia(AML). Method: Combination of autologous DC and CIK cells was used to treat 20 cases of refractory
and recurrent patients with acute myeloid leukemia, At the same time, 20 cases of refractory and recurrent patients with AML treated by
same plan were set as the control group. Clinical efficacy and Qualicty of life (KPS) were observed after 4 weeks in two group. T cell
subsets(CD3+, CD3+CD4+, CD3+CD8+, CD3+CD56+) and Cytokine (IL-12, IL-2, IL-7, IFN-酌and TNF-琢) were detected after 4 weeks and
before treatment with DC and CIK.Results: ① The effective rate and KPS in refractory and recurrent patients with AML were
significantly higher than those of the control group (P＜0.05). All patients with adverse reactions were mild and tolerable. ② After 4
weeks’treatment with DC and CIK, the percentage of T cell subsets (CD3 +,CD3+CD4+, CD3+CD8+ and CD3+ CD56+) and Cytokine
(IL-12, IL-2, IL-7, IFN-酌and TNF-琢) were improved than before treatment，CD3+, CD3+CD56+ and IL-12, IL-7 improved significantly
(P＜0.05). Conclusion: DC and CIK cell immunotherapy was a safe and efficacious therapeutic measure in the treatment of refractory
and recurrent adult patients with AML. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
